January 2024, Vol 14, No 1

San Diego—Ibrutinib plus venetoclax significantly improved progression-free (PFS) and overall survival (OS) compared with a standard fludarabine, cyclophosphamide, and rituximab (FCR) regimen in patients with untreated chronic lymphocytic leukemia (CLL) and now represents a new standard for treatment of the disease. Read More ›

At the 13th Annual Association for Value Based Cancer Care Summit in 2023, held October 18-20, 2023, in New York City, Scott Gottlieb, MD, Former Commissioner of the FDA, gave the keynote lecture on how to foster innovation in oncology. Read More ›

The Cholangiocarcinoma Foundation (CCF) is celebrating the 1000th mentor–mentee match and 6 years of their mentoring program, CholangioConnect. CCF has developed unique resources to help patients and caregivers navigate their healthcare journeys. Read More ›

Adjuvant ado-trastuzumab emtansine (T-DM1) continued to improve invasive disease-free survival (IDFS) and overall survival (OS) versus adjuvant trastuzumab in patients with high-risk HER2-positive early breast cancer, according to 7-year follow-up of the phase 3 KATHERINE trial. Read More ›

San Antonio—Dual HER2-directed therapy with tucatinib and trastuzumab emtansine (T-DM1) extended progression-free survival (PFS) compared with T-DM1 alone in patients with previously treated, resectable, locally advanced or metastatic HER2-positive breast cancer. Read More ›

San Antonio—A 9-month twice weekly structured exercise program improved measures of fatigue and quality of life among patients with metastatic breast cancer, according to a randomized controlled trial presented by Anne M. May, PhD, professor, Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands, at the 2023 San Antonio Breast Cancer Symposium. Read More ›

San Diego—In the first randomized trial conducted in patients with myelofibrosis who have not previously been treated with a JAK inhibitor, twice as many who received an investigational targeted agent (navitoclax) in addition to a JAK inhibitor had a clinically significant reduction in spleen size compared with those who received JAK inhibitor monotherapy. Read More ›

San Diego—Patients with relapsed or refractory acute leukemia with rearrangement in the KMT2Ar gene, an aggressive and difficult-to-treat leukemia, had an overall response rate of 63% when treated with the investigational agent revumenib, according to data from the single-arm pivotal phase 2 AUGMENT-101 study presented by Ibrahim Aldoss, MD, associate professor, Department of Hematology and Stem Cell Transplant, City of Hope National Medical Center, Duarte, California, at the 65th American Society of Hematology Annual Meeting. Read More ›

A new study has revealed some important information about the behavior of one of the most notorious forms of cancer. Pancreatic cancer, the study found, can readily turn to an alternate source of energy to survive when its primary source, the sugar molecule glucose, is in short supply. Read More ›

On November 27, 2023, the FDA approved nirogacestat (Ogsiveo; SpringWorks Therapeutics) for adults with progressing desmoid tumors who require systemic treatment. Read More ›